• Claudio Carallo, Fabiola Pugliese, Elisa Vettorato, Cesare Tripolino, Livia Delle Donne, Giovanni Guarrera, Walter Spagnolli, and Susanna Cozzio.
• Metabolic Diseases Unit, Department of Clinical and Experimental Medicine, Magna Græcia University, Catanzaro, Italy numemaca@yahoo.it.
• J. Investig. Med. 2021 Mar 23.

AbstractCoronavirus disease 2019 (COVID-19) is a new viral disease complicating with acute thrombophylic conditions, probably also via an inflammatory burden. Anticoagulants are efficacious, but their optimal preventive doses are unknown. The present study was aimed to compare different enoxaparin doses/kg of body weight in the prevention of clot complications in COVID-19 pneumonia. Retrospective data from a cohort of adult patients hospitalized for COVID-19 pneumonia, never underwent to oropharyngeal intubation before admission, were collected in an Internal Medicine environments equipped for non-invasive ventilation. Unfavorable outcomes were considered as: deep venous thrombosis, myocardial infarction, stroke, pulmonary embolism, cardiovascular death. Fourteen clinical thromboembolic events among 42 hospitalized patients were observed. Patients were divided into two group on the basis of median heparin dose (0.5 mg-or 50 IU-for kg). The decision about heparin dosing was patient by patient. Higher enoxaparin therapy (mean 0.62±0.16 mg/kg) showed a better thromboprophylactic action (HR=0.2, p=0.04) with respect to lower doses (mean 0.42±0.06 mg/kg), independently from the clinical presentation of the disease. Therefore, COVID-19 pneumonia might request higher enoxaparin doses to reduce thromboembolic events in hospitalized patients, even if outside intensive care units.© American Federation for Medical Research 2021. No commercial re-use. See rights and permissions. Published by BMJ.

2 keywords...

hide…